Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Neuroscience
Alkermes acquires HDAC inhibitor developer Rodin
by Lisa M. Jarvis
November 23, 2019
| A version of this story appeared in
Volume 97, Issue 46
Alkermes is bolstering its neuroscience pipeline by acquiring Rodin Therapeutics, a biotech firm developing treatments for diseases caused by synaptic dysfunction. Rodin investors will get $100 million up front and up to $850 million in future payments based on the progress of Rodin’s small molecules, which selectively inhibit histone deacetylase (HDAC) complexes. Alkermes noted that it might prioritize the development of preclinical HDAC inhibitors over Rodin’s lead candidate, RDN-929, which is in Phase I studies.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X